Tiger Brokers

BUZZ-PDS Biotech rises as it seeks faster FDA nod for cancer drug

Reuters
Jan 09
BUZZ-PDS Biotech rises as it seeks faster FDA nod for cancer drug

** Shares of drugmaker PDS Biotech PDSB.O rise 4.7% to $1.04 premarket

** Co says it has asked U.S. FDA to approve changes to its late-stage trial of its experimental cancer drug, PDS0101

** Co's PDS0101 aims to treat advanced head and neck cancer caused by HPV16

** Amended plan focuses on progression-free survival to speed approval, co says

** PDSB says FDA held constructive meeting on potential accelerated approval

** "We believe that including progression-free survival as a main goal offers an important opportunity to shorten the trial," CEO Frank Bedu-Addo says

** As of last close, stock down ~53% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10